10-Q: Niagen Bioscience Soars in Q3 2025 with Triple-Digit Profit Growth

Sentiment:

Quarterly Report 4 November 2025 4:01 PM

Niagen Bioscience, Inc. reported significant financial improvements for the third quarter and first nine months of 2025, driven by strong sales growth across its consumer products and ingredients segments.

Capital raiseManagement stated that the company "may, however, seek additional capital within the next twelve months, both to fund its projected operating plans after the next twelve months and/or to fund the Company’s longer-term strategic objectives."The company has an At Market Issuance Sales Agreement (ATM Facility) with Raymond James & Associates, Inc. and Roth Capital Partners, LLC, which could be used for equity financing.The company also mentioned potential debt financings or collaborative agreements as sources of additional funds.

Better than expectedNet sales increased by 33% for the three months and 36% for the nine months ended September 30, 2025, significantly outpacing prior year periods.Net income surged by 144% for the three months and 866% for the nine months ended September 30, 2025, demonstrating substantial profitability improvement.Operating income showed remarkable growth, increasing by 164% for the three months and 1882% for the nine months, indicating enhanced operational efficiency.Cash and cash equivalents increased by $19.630 million since year-end 2024, strengthening the company's liquidity position.The accumulated deficit was reduced by $13.250 million, reflecting a strong move towards sustained profitability.

Summary

Net sales increased 33% to $33.986 million for the three months ended September 30, 2025, and 36% to $95.584 million for the nine months ended September 30, 2025, compared to the same periods in 2024.
Net income surged 144% to $4.578 million for the three months and 866% to $13.250 million for the nine months ended September 30, 2025.
Basic earnings per share rose to $0.06 for the quarter and $0.17 for the nine months, up from $0.02 in both prior-year periods.
Cash and cash equivalents increased to $64.290 million as of September 30, 2025, from $44.660 million at December 31, 2024.
The company settled the California Action legal dispute with Elysium Health, receiving $2.650 million in two installments by March 28, 2025.
A new exclusive supply agreement with W. R. Grace & Co.-Conn. requires the purchase of approximately $33.6 million in NRCL inventory through September 30, 2026.
The accumulated deficit was reduced by $13.250 million to $168.660 million as of September 30, 2025.

Sentiment

Score: 8

Explanation: The company demonstrated exceptional financial performance with strong revenue growth, significant increases in net income and operating income, and improved cash position. The resolution of the California legal action is a positive, though the ongoing Delaware patent dispute and supplier concentration remain areas of concern. Overall, the results indicate robust operational execution and a positive trajectory.

Positives

Strong revenue growth: 33% for Q3 and 36% for YTD.
Significant net income increase: 144% for Q3 and 866% for YTD.
Improved gross profit margins: Total cost of sales as a percentage of net sales improved by 100 basis points for Q3 and 270 basis points for YTD.
Positive operating cash flow: $12.8 million provided by operating activities for the nine months.
Increased cash position: $64.1 million unrestricted cash and cash equivalents.
Successful resolution of California Action litigation with Elysium Health, resulting in a $2.650 million settlement payment received.
Consumer Products segment sales increased by $7.9 million (Q3) and $16.1 million (YTD), driven by e-commerce and distributor partners.
Ingredients segment sales increased by $0.5 million (Q3) and $8.9 million (YTD), primarily from food-grade Niagen partners.
Analytical Reference Standards and Services segment returned to operating income profitability for the nine months ended September 30, 2025, with operating income of $288k compared to a loss of $(163)k in the prior year.
Reduction in accumulated deficit by $13.250 million.

Negatives

Ongoing legal dispute with Elysium Health regarding patent infringement in Delaware, with a final judgment against the company for $9.2 million in attorneys' fees and costs, plus interest, which is currently under appeal.
Concentration risk in trade receivables: 64.9% of total trade receivables concentrated among three customers as of September 30, 2025.
Dependence on a single supplier (W.R. Grace) for NRC, with patents limiting alternative sourcing.
Deferred revenue from NHSc showed a reversal of $(95)k for the nine months ended September 30, 2025, compared to $732k recognized in the prior year.
History of recurring operating losses and negative cash flows from operating activities (though positive in current period, the risk factor highlights the historical trend).
Pharmaceutical-grade Niagen sales decreased slightly by $0.4 million during the three-month period, though improved over nine months.

Risks

History of operating losses and potential need for additional financing, with no assurance of availability on favorable terms.
Interruptions or declines in business with major customers could materially harm financial results due to high concentration of trade receivables.
Global, market, and economic conditions (inflation, interest rates, geopolitical issues) may negatively impact business, consumer demand, and ability to collect receivables.
Future success is largely dependent on sales of the Tru Niagen product.
The success of the consumer product and ingredient business is linked to the size and growth rate of the wellness industry market.
Significant competition from larger companies with greater resources, potential new technologies, and misleading marketing practices by competitors.
Operating results may fluctuate significantly due to various unpredictable factors.
Reliance on a single supplier (W.R. Grace) for NRC and a limited number of third-party suppliers for raw materials.
Failure by outsourcing facilities producing pharmaceutical-grade Niagen to adequately perform obligations could harm the business.
Unfavorable publicity or consumer perception regarding products or the dietary supplement industry could adversely affect demand.
Potential for material product liability claims or class action litigation.
Risks associated with international trade and importation issues due to foreign suppliers.
Uncertainty in protecting intellectual property, including patents and licenses, and potential claims of infringement from others.
Changes in government regulation or practices relating to the pharmaceutical, dietary supplement, food, and cosmetic industries, including FDA decisions on ingredients like NMN.
Compliance with stringent and changing global privacy and data security laws and regulations.
Market price volatility of common stock.
Potential dilution from outstanding options, restricted stock units, and future equity offerings.
Limitations on the ability to use net operating loss (NOL) carryforwards.
Potential for securities class action litigation.
Failure to establish and maintain effective internal control over financial reporting.
Limited operating history and uncertainties in developing successful channels in China.
Environmental, social, and governance (ESG) matters may impact business and reputation.
Changes in tax laws or regulations.

Future Outlook

Management anticipates that current unrestricted cash and cash equivalents, combined with cash generated from net sales, will be sufficient to meet financial obligations for at least the next twelve months. The company may seek additional capital within the next twelve months to fund projected operating plans beyond that period and longer-term strategic objectives. Research and development investments are expected to fluctuate based on the timing and scope of specific projects and clinical development activities. The company continues to monitor IRS guidance on ERTC claims and is evaluating the impact of new FASB ASUs on its financial statements.

Management Comments

Anticipate that our current unrestricted cash and cash equivalents and cash to be generated from net sales will be sufficient to meet our financial obligations as they become due over at least the next twelve months.
May, however, seek additional capital within the next twelve months, both to fund its projected operating plans after the next twelve months and/or to fund the Company’s longer-term strategic objectives.
We continue to anticipate fluctuations in R&D investment based on the timing and scope of specific projects, clinical development activities, and internal resource allocation.
We believe the Court abused its discretion in granting the award [of attorneys' fees to Elysium].
We believe our automatic renewal flow complies with all applicable laws, including recent amendments effective July 2025, and believes the allegations lack merit.
We do not believe that the ultimate resolution of this matter [licensor dispute] will be material to the Company’s results of operations, financial condition or cash flows.
We do not expect the adoption of this guidance [ASU 2025-05, ASU 2025-06] to have a material impact on our consolidated financial statements and accompanying notes.
We have evaluated the relevant provisions [of OBBBA] and does not anticipate a significant impact on its consolidated income tax position, effective tax rate, or valuation allowance as a result of the legislation.

Industry Context

Niagen Bioscience operates in the growing healthy aging and dietary supplement market, pioneering research on NAD+ precursors like Nicotinamide Riboside Chloride (NRC). The company's focus on scientifically validated ingredients and consumer products like Tru Niagen positions it within a competitive landscape where consumer perception and regulatory clarity (e.g., FDA's stance on NMN) are critical. The expansion into pharmaceutical-grade Niagen for healthcare practitioners and 503B outsourcing facilities aligns with the increasing demand for specialized wellness and medical nutritional products. The company's extensive research collaborations through CERP and its Scientific Advisory Board underscore its commitment to scientific leadership in the NAD+ space, differentiating it from competitors who may engage in misleading marketing practices.

Comparison to Industry Standards

The company's strong revenue growth (33% Q3, 36% YTD) and significant net income increase (144% Q3, 866% YTD) suggest outperformance compared to many established players in the broader dietary supplement industry, which often see more moderate growth.
The improvement in gross profit margins (100-270 basis points) indicates effective cost management and favorable product mix shifts, which is a positive sign in an industry often facing inflationary pressures.
The company's investment in R&D, even with fluctuations, and its extensive research collaborations (CERP with over 300 institutions, Scientific Advisory Board with Nobel Laureates) set a high standard for scientific validation in the wellness industry, distinguishing it from companies that may rely less on rigorous scientific backing.
The legal challenges, particularly the $9.2 million judgment for attorneys' fees in the Delaware patent case, highlight the intense intellectual property battles common in the high-value ingredient and pharmaceutical precursor markets, where patent protection is crucial for competitive advantage.
The reliance on a single supplier for NRC (W.R. Grace) is a notable supply chain risk, which is not uncommon for proprietary ingredients but requires careful management compared to diversified sourcing strategies seen in more mature industries.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer	NA	Robert Fried	February 25, 2025	Increased base salary and target performance bonus opportunity, and granted market performance stock units as part of an amended executive employment agreement.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Equity Incentive Plan Amendment	Stockholders approved an amendment to the 2017 Equity Incentive Plan to increase the number of shares available for issuance by 4.75 million shares of common stock.	June 24, 2025	Increases the pool of shares for equity compensation, potentially leading to further dilution but also enabling the company to attract and retain talent.
Employee Stock Purchase Plan (ESPP) Approval	Stockholders approved the Niagen Bioscience, Inc. Employee Stock Purchase Plan (ESPP), reserving 650,000 shares of common stock for issuance.	June 24, 2025	Provides eligible employees with an opportunity to purchase company stock at a discount, fostering employee ownership and alignment with shareholder interests, but also represents potential future dilution.

Legal Proceedings

California Action (Elysium Health, LLC): A lawsuit alleging breach of supply agreements, trade secret misappropriation, and breach of confidentiality by Elysium and Mark Morris. Elysium counterclaimed for breach of supply agreement and fraudulent inducement. The jury found Elysium liable for $3.0 million and Morris for $17,307, while Niagen Bioscience was liable for $625,000 (refunds/credits) and $250,000 (fraudulent inducement) plus $1,025,000 in punitive damages. A binding settlement agreement was reached on December 24, 2024, requiring Elysium to pay $2,650,000 in two installments, which have both been received. The judgment was fully satisfied on April 4, 2025.
Delaware Patent Infringement Action (Elysium Health, Inc.): Niagen Bioscience and Trustees of Dartmouth College filed a patent infringement complaint against Elysium Health alleging infringement of U.S. Patent Nos. 8,197,807 and 8,383,086. The court of appeals affirmed summary judgment that the patent claims are invalid. The Supreme Court denied certiorari. On October 28, 2024, the court issued a final judgment granting Elysium $9.2 million in attorneys' fees and costs, plus judgment interest. Niagen Bioscience appealed this final judgment on November 25, 2024, and believes the court abused its discretion. A contingent liability of approximately $10.4 million (inclusive of post-judgment interest) is possible if the appeal is unsuccessful, with no accrual recorded as of September 30, 2025.
Licensor Dispute: In September 2019, a licensor claimed $1.6 million plus interest for sublicense fees. The company believes it does not owe these fees and does not expect the resolution to be material.
California Business and Professions Code Allegations: In August 2025, a demand letter was received, followed by a class action lawsuit on October 31, 2025, alleging violations related to automatic renewal and cancellation disclosures on the e-commerce platform. The company believes its practices comply with applicable laws and that the allegations lack merit, not expecting a material impact.

Related Party Transactions

A.S. Watson Group was considered a related party prior to August 20, 2024, due to common ownership. This entity sold its ownership on August 20, 2024, ceasing the related party status.
Sales to A.S. Watson Group were $2.0 million for the three months ended September 30, 2024, and $8.7 million for the nine months ended September 30, 2024 (excluding sales after August 20, 2024).
As of September 30, 2025, A.S. Watson Group accounted for 39.0% of total trade receivables, net, down from 47.6% at December 31, 2024.
No trade receivables connected to related parties as of September 30, 2025 or December 31, 2024.

Stakeholder Impact

Shareholders: Positive impact from strong financial performance, increased net income, and reduced accumulated deficit. Potential dilution from future equity offerings and exercise of options/RSUs. Risk of stock price volatility due to various factors.
Employees: Positive impact from the approval of the Employee Stock Purchase Plan (ESPP) and increased compensation for the CEO, potentially signaling broader benefits.
Customers: Continued supply of Niagen products through the Grace Supply Agreement. Potential impact from concentration of trade receivables if major customers face financial difficulties.
Suppliers: W.R. Grace benefits from the exclusive supply agreement for NRCL, with significant purchase commitments.
Creditors: Improved financial health and liquidity reduce credit risk.
Regulatory Bodies: Ongoing compliance with SEC filing requirements and monitoring of new FASB accounting standards. Continued engagement with FDA regarding pharmaceutical-grade Niagen and IND application for AT.

Next Steps

Continue monitoring guidance and communications from the IRS regarding ERTC claims.
Evaluate the impact of newly issued FASB ASUs on consolidated financial statements and disclosures.
Make good faith efforts to execute a supplemental agreement with Grace for a world-wide, royalty-bearing, exclusive, non-transferable and sub-licensable license to Grace's patents covering NRCL's manufacture.
The Federal Circuit has not yet scheduled oral argument for the appeal of the Delaware patent infringement judgment.
The company may seek additional capital within the next twelve months to fund projected operating plans and longer-term strategic objectives.
The ESPP's first offering period has not yet been extended.

Key Dates

Date	Description
2013	Commercialized food-grade Niagen.
February 3, 2014	Date of Niagen Supply Agreement and Trademark License and Royalty Agreement with Elysium Health.
June 26, 2014	Date of pTeroPure Supply Agreement with Elysium Health.
December 29, 2016	Niagen Bioscience filed a complaint against Elysium Health in California Action.
January 25, 2017	Elysium filed an answer and counterclaims in response to the California Action complaint.
2017	Launched Tru Niagen.
September 17, 2018	Niagen Bioscience and Trustees of Dartmouth College filed a patent infringement complaint against Elysium Health in Delaware.
November 27, 2018	Niagen Bioscience filed a fifth amended complaint in California Action, adding Mark Morris as a defendant.
December 21, 2018	Defendants moved to dismiss in California Action.
December 19, 2018	Original supply agreement with NESTEC Ltd. (now NHSc).
January 2019	Grace was issued patents related to the crystalline form of NR chloride.
February 4, 2019	Court denied Defendants' motion to dismiss in California Action.
February 19, 2019	Defendants filed answer to Niagen Bioscience's fifth amended complaint in California Action.
March 5, 2019	Niagen Bioscience filed answer to Elysium's restated counterclaims in California Action.
August 9, 2019	Discovery closed in California Action.
August 16, 2019	Parties filed motions for partial summary judgment in California Action.
September 2019	Company received a letter from a licensor stating $1.6 million owed for sublicense fees.
November 1, 2019	Niagen Bioscience filed a motion to lift the stay in Delaware patent infringement action.
January 16, 2020	Court granted both parties' motions for summary judgment in part and denied in part in California Action.
March 2020	CARES Act signed into law, providing ERTC.
November 18, 2020	Court set trial to begin on September 21, 2021, in California Action.
September 21, 2021	Jury trial commenced in California Action.
September 27, 2021	Jury returned a verdict in California Action.
October 25, 2021	Niagen Bioscience informed court of request for prejudgment interest in California Action.
November 2, 2021	Niagen Bioscience filed notice of appeal in Delaware patent infringement action.
February 10, 2022	Court denied Niagen Bioscience's motion for prejudgment interest in California Action.
February 18, 2022	Niagen Bioscience and Elysium jointly filed notice of motion to enforce settlement agreement in SDNY Court.
April 22, 2022	SDNY Court granted Niagen Bioscience's motion to enforce settlement agreement.
August 2022	Company filed a claim for ERTC.
August 22, 2022	Niagen Bioscience filed motion for entry of judgment in California Action.
September 13, 2022	Court denied Niagen Bioscience's motion for entry of judgment in California Action.
September 28, 2022	California Action stayed pending Federal Circuit Appeal.
October 10, 2022	Amended and restated supply agreement with NHSc.
February 13, 2023	Court of appeals affirmed district court's decision in Delaware patent infringement action.
March 15, 2023	Niagen Bioscience filed petition for panel rehearing and/or rehearing en banc in Delaware patent infringement action.
May 10, 2023	Court of appeals denied petition in Delaware patent infringement action.
May 17, 2023	Court of appeals issued mandate in Delaware patent infringement action.
June 16, 2023	Elysium filed bill of costs and motion for attorneys' fees in Delaware patent infringement action.
September 7, 2023	Niagen Bioscience filed a petition for writ of certiorari to Supreme Court in Delaware patent infringement action.
September 14, 2023	IRS announced immediate halt in processing new ERTC claims.
October 16, 2023	Supreme Court denied petition for writ of certiorari in Delaware patent infringement action.
Early 2024	California Action stay lifted.
February 23, 2024	Joint status report and stipulation filed in California Action.
February 26, 2024	Court approved briefing schedule in California Action.
March 4, 2024	Company's 2024 Annual Report on Form 10-K filed with the SEC.
March 22, 2024	Previously executed Quality Agreement with Grace.
March 25, 2024	Court granted Elysium's motion for attorneys' fees and costs in Delaware patent infringement action.
April 1, 2024	Launch of Niagen Plus product line.
April 26, 2024	Niagen Bioscience filed motion for entry of final judgment in California Action.
August 13, 2024	Court granted Niagen Bioscience's motion for entry of final judgment and entered judgment requiring Elysium to pay $2,500,000 in California Action.
August 20, 2024	Entity sold its ownership in the Company, A.S. Watson Group ceased to be a related party.
September 3, 2024	Niagen Bioscience filed motion for attorneys fees, costs, and interest in California Action.
September 11, 2024	Elysium and Mark Morris filed notice of appeal in California Action.
September 25, 2024	Niagen Bioscience filed notice of conditional cross-appeal in California Action.
October 1, 2024	Parties submitted joint motion for entry of judgment in Delaware patent infringement action.
October 8, 2024	Court granted Niagen Bioscience's request for interest ($21,768.82) and denied attorneys' fees/costs in California Action.
October 28, 2024	Court issued final judgment resolving amount of fees and costs ($9.2 million plus interest) in Delaware patent infringement action.
November 7, 2024	Niagen Bioscience filed notice of appeal from court's order denying attorneys' fees/costs in California Action.
November 25, 2024	Niagen Bioscience appealed final judgment in Delaware patent infringement action to U.S. Court of Appeals for the Federal Circuit.
December 4, 2024	Niagen Bioscience filed unopposed motion to approve bond and stay enforcement in Delaware patent infringement action.
December 6, 2024	Court granted motion to approve bond and stay enforcement in Delaware patent infringement action.
December 24, 2024	Binding settlement agreement reached to resolve California Action and Appeals.
December 26, 2024	Parties filed joint stipulation to amend judgment in California Action.
December 27, 2024	Court vacated August 13, 2024 judgment and entered amended judgment in California Action; Company received First Installment of $1,325,000 from Elysium.
December 30, 2024	Parties filed stipulated motion to voluntarily dismiss Appeals in Ninth Circuit.
December 31, 2024	Ninth Circuit dismissed Appeals in California Action.
January 1, 2025	Commencement of offering periods for ESPP.
February 25, 2025	Granted Robert Fried 1,518,600 market performance stock units (PSUs) and increased his base salary and target bonus.
February 26, 2025	Niagen Bioscience filed its opening appeal brief in Delaware patent infringement action.
March 21, 2025	Elysium filed its response brief in Delaware patent infringement action.
March 28, 2025	Company received Second Installment of $1,325,000 from Elysium.
April 1, 2025	Effective date of Grace Supply Agreement.
April 4, 2025	Company filed acknowledgement of satisfaction of judgment in California Action.
April 25, 2025	Niagen Bioscience filed its reply brief in Delaware patent infringement action.
June 24, 2025	Stockholders approved the Niagen Bioscience, Inc. Employee Stock Purchase Plan (ESPP) and an amendment to the 2017 Equity Incentive Plan.
July 1, 2025	Commencement of offering periods for ESPP.
July 4, 2025	One Big Beautiful Bill Act (OBBBA) signed into law.
July 25, 2025	Company executed Sales Agreement (Grace Supply Agreement) with W. R. Grace & Co.-Conn.
August 2025	Company received a demand letter alleging violations of California's Business and Professions Code.
October 31, 2025	Class action lawsuit filed related to California's Business and Professions Code allegations.
November 3, 2025	79,806,139 shares of common stock issued and outstanding.
November 4, 2025	Filing date of the 10-Q report.
December 15, 2024	Effective date for ASU 2023-09 (Income Taxes) for annual periods beginning after this date; effective date for ASU 2024-02 (Codification Improvements) for annual periods beginning after this date; effective date for ASU 2025-05 (Credit Losses) for annual periods beginning after this date.
December 15, 2026	Effective date for ASU 2024-03 (Expense Disaggregation Disclosures) for annual periods beginning after this date.
December 15, 2027	Effective date for ASU 2025-06 (Internal-Use Software) for annual periods beginning after this date; effective date for ASU 2024-03 (Expense Disaggregation Disclosures) for interim reporting periods beginning after this date.
June 30, 2027	Effective date for ASU 2023-06 (Disclosure Improvements) if SEC has not removed requirements by this date.
April 30, 2029	Initial term end date for Grace Supply Agreement.
October 31, 2030	Amended lease in Longmont, Colorado extends through this date.

Recommendation

strong buy

The company has demonstrated exceptional financial performance, with triple-digit growth in net income and operating income for both the quarter and year-to-date periods. Revenue growth is robust across key segments, and the company has significantly improved its cash position and reduced its accumulated deficit. The successful resolution of the California legal dispute removes a significant overhang. While the ongoing Delaware patent appeal and customer concentration are risks, the strong operational execution, market leadership in NAD+ science, and positive financial trajectory suggest a compelling investment opportunity. The company's ability to generate positive operating cash flow and its stated sufficiency of cash for the next twelve months further bolster its financial stability.

Keywords

Niagen Bioscience, NAD+, Nicotinamide Riboside Chloride, Tru Niagen, Dietary Supplements, Pharmaceutical-grade Niagen, Healthy Aging, SEC Filing, 10-Q, Financial Results, Consumer Products, Ingredients, Biotechnology, Wellness Industry, Patent Litigation, W.R. Grace, Elysium Health, Employee Stock Purchase Plan, ERTC, e-commerce

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.